Skip to main content
What is PSMA-positive metastatic prostate cancer?

What is PSMA-positive metastatic prostate cancer?

  • Metastatic castration-resistant prostate cancer (mCRPC) is a type of prostate cancer that has spread to other parts of your body and is no longer responding to hormone treatment that lowers testosterone

  • PSMA (prostate-specific membrane antigen) is a biomarker that sits on the outside of prostate cancer cells and is detected by a PSMA positron emission tomography (PET) scan

If your prostate cancer cells have an abundance of PSMA, it means your mCRPC is PSMA positive (PSMA+). PSMA+ cancer cells can be targeted with PLUVICTO.

Noncancerous PSMA+ cells and other surrounding cells will also be impacted.

PSMA is a biomarker found in more than 80% of men with prostate cancer.
You can find out if your prostate cancer is PSMA+ by having a PSMA PET scan 

Ask your doctor about treating your metastatic prostate cancer with PLUVICTO.

Important Safety Information

What is the most important information I should know about PLUVICTO?

Use of PLUVICTO involves exposure to radioactivity. Long-term, accruing radiation exposure is associated with an increased risk for cancer...

Approved Use

What is PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan)?

PLUVICTO is a radiopharmaceutical used to treat adults with an advanced cancer called prostate-specific membrane antigen­–­positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that...